NEW YORK - Teva Pharmaceutical Industries Ltd. said Wednesday that it received Food and Drug Administration approval for a generic version of Galderma's acne treatment Differin.

Teva, based in Israel and with U.S. headquarters in North Wales, Montgomery County, said the product has annual sales of about $91 million in the United States.

Shares of Teva were up 49 cents to $54.77.